Collegium Pharmaceutical Is A Relatively Safe Opioid Pick For 2020

|
About: Collegium Pharmaceutical, Inc. (COLL), Includes: ENDP, JNJ
by: Healthcare on the Move
This article is exclusive for subscribers.
Healthcare on the Move
Biotech, healthcare, value, long/short equity
Summary

Xtampza ER's growth prospects will make up for Nucynta’s downfall.

The company is demonstrating robust commercial execution.

Investors, however, should consider certain risks.

Today, we will be studying why Collegium Pharmaceutical (COLL) is an attractive pick in 2020, despite being an opioid player.

Company overview

Collegium Pharmaceutical is a specialty pharmaceutical company with a focus on